[go: up one dir, main page]

AU2001250573A1 - Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone - Google Patents

Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone

Info

Publication number
AU2001250573A1
AU2001250573A1 AU2001250573A AU5057301A AU2001250573A1 AU 2001250573 A1 AU2001250573 A1 AU 2001250573A1 AU 2001250573 A AU2001250573 A AU 2001250573A AU 5057301 A AU5057301 A AU 5057301A AU 2001250573 A1 AU2001250573 A1 AU 2001250573A1
Authority
AU
Australia
Prior art keywords
phanquinone
mmps
action
treatment
pathological conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001250573A
Inventor
Michel Xilinas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001250573A1 publication Critical patent/AU2001250573A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001250573A 2000-04-28 2001-04-30 Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone Abandoned AU2001250573A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000704 2000-04-28
DKPA200000704 2000-04-28
PCT/IB2001/000715 WO2001082912A2 (en) 2000-04-28 2001-04-30 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE

Publications (1)

Publication Number Publication Date
AU2001250573A1 true AU2001250573A1 (en) 2001-11-12

Family

ID=8159457

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001250573A Abandoned AU2001250573A1 (en) 2000-04-28 2001-04-30 Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone

Country Status (2)

Country Link
AU (1) AU2001250573A1 (en)
WO (1) WO2001082912A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007040B1 (en) 1997-08-21 2002-05-08 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
ATE475714T1 (en) 1998-12-09 2010-08-15 Phyton Holdings Llc METHOD FOR PRODUCING GLYCOPROTEIN WITH HUMAN GLYCOSYLATION IMAGE
WO2001031045A1 (en) 1999-10-26 2001-05-03 Plant Research International B.V. Mammalian-type glycosylation in plants
CN100385006C (en) 2001-01-19 2008-04-30 陶氏化学公司 Method for secretory production of glycoproteins with human sugar chains using plant cells
EP1485492B1 (en) 2002-03-19 2011-12-21 Stichting Dienst Landbouwkundig Onderzoek Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta(1,4)-n-acetylglucosaminyltransferase iii) expression in plants
JP4532118B2 (en) 2002-03-19 2010-08-25 スティヒティング ディーンスト ランドバウクンディフ オンデルズーク Optimization of glycan processing in plants
CL2003002461A1 (en) 2002-11-27 2005-01-07 Dow Chemical Company Agroscien IMMUNOGLOBULIN THAT UNDERSTANDS AT LEAST ONE AFUCOSILATED GLICAN, COMPOSITION THAT CONTAINS IT, NUCLEOTIDIC SEQUENCE AND VECTOR THAT UNDERSTANDS IT, PROCEDURE TO PRODUCE IMMUNOGLOBULIN SAID IN PLANTS.
WO2006117660A2 (en) * 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
NZ580510A (en) 2007-04-17 2011-06-30 Stichting Dienst Landbouwkundi Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007040B1 (en) * 1997-08-21 2002-05-08 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
ES2234559T3 (en) * 1999-01-07 2005-07-01 P.N. Gerolymatos S.A. USE OF FANQUINONA FOR THE TREATMENT OR PREVENTION OF THE DETERIORATION OF THE MEMORY.

Also Published As

Publication number Publication date
WO2001082912A3 (en) 2002-05-16
WO2001082912A2 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
AU2001260513A1 (en) Microcapsule well treatment
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
MA26812A1 (en) PYRIMIDINE-2,4,6-TRIONES INHIBITORS OF METALLOPROTEINASES
GB0007193D0 (en) Treatment of movrmrnt disorders
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2001250573A1 (en) Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone
AUPR074500A0 (en) Treatment of t cell disorders
AU2001265182A1 (en) Inhibitors of matrix metalloproteinases
AU2001250571A1 (en) Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol
AU2001274894A1 (en) Novel matrix metalloproteinases
HK1046238A1 (en) Calcilytic compounds
AU2001274344A1 (en) Tissue inhibitors of matrix metalloproteinases
AU2002351430A1 (en) Electrochemically activated water for the treatment of cystitis
AU2001245414A1 (en) Treatment of allergies
AU3899100A (en) Treatment of hyperactivity disorders
AU2002335823A1 (en) Antisense modulation of matrix metalloproteinase 1 expression
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
AU2001292601A1 (en) Human matrix metalloproteinase
AU5812601A (en) Treatment of il-10 deficiencies
AU2002241776A1 (en) Treatment of disease by inducing cell apoptosis
AU2003300851A1 (en) Modulation of matrix metalloproteinase 11 expression
AU2001253560A1 (en) Methods of treatment
AU2002245331A1 (en) Treatment of disease by inducing cell apoptosis
AU2002211600A1 (en) Gene expression profiling of antidepressant action in the brain